Cardiotoxicity in patients with metastatic melanoma treated with BRAF/MEK inhibitors: a real-world analysis of incidence, risk factors, and reversibility
DOI:
https://doi.org/10.2340/1651-226X.2025.42567Keywords:
BRAF/MEK inhibition, cardiotoxicity, malignant melanoma, echocardiography, multigated acquisition scan, oncocardiology, antineoplastic therapyAbstract
Background: BRAF/MEK inhibitors (BRAFi/MEKi) improve outcome in patients with BRAF-mutated metastatic melanoma but are associated with cardiotoxicity, leading to a decline in left ventricular ejection fraction (LVEF). This study aimed to evaluate the incidence, timeline, risk factors, and reversibility of BRAFi/MEKi-induced cardiotoxicity in a real-world setting.
Patients/materials and methods: Patients with metastatic melanoma (n = 170) treated with Encorafenib/Binimetinib, Vemurafenib/Cobimetinib, or Dabrafenib/Trametinib at Aarhus and Odense University Hospital, Denmark, from 2015 to 2023 were included. Cardiac function was assessed at baseline and every 3 months during treatment with either echocardiograms or multigated acquisition scans. Cardiotoxicity was defined as a reduction of LVEF by ≥10 percentage points (pp) to an LVEF < 50% (Major cardiotoxicity) or a reduction of LVEF by ≥15 pp but remaining > 50% (Minor cardiotoxicity).
Results: Cardiotoxicity occurred in 21% of patients, with 14% experiencing major cardiotoxicity. The mean time to LVEF decline was 187 days, with 92% of major cardiotoxicity cases occurring within the first year. Cardiotoxicity was reversible in 79% of patients following dose reduction, treatment pauses, heart failure therapy, or continued treatment with monitoring. Baseline atrial fibrillation (odds ratio 13.67, p = 0.008) was identified as a risk factor for major cardiotoxicity.
Interpretation: BRAFi/MEKi-induced cardiotoxicity is a significant but manageable complication, often reversible with timely interventions. Routine LVEF monitoring is recommended. The majority (92%) of major cardiac events were diagnosed within the first year of treatment, which might warrant a discontinuation of routine LVEF monitoring after 1 year of BRAFi/MEKi treatment.
Downloads
References
Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma. Lancet. 2018;392(10151):971–84.
https://doi.org/10.1016/s0140-6736(18)31559-9 DOI: https://doi.org/10.1016/S0140-6736(18)31559-9
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.
https://doi.org/10.3322/caac.21763 DOI: https://doi.org/10.3322/caac.21763
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54.
https://doi.org/10.1038/nature00766 DOI: https://doi.org/10.1038/nature00766
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–32.
https://doi.org/10.1016/s1470-2045(14)70012-9 DOI: https://doi.org/10.1016/S1470-2045(14)70012-9
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–65.
https://doi.org/10.1016/s0140-6736(12)60868-x DOI: https://doi.org/10.1016/S0140-6736(12)60868-X
Kunz M, Dannemann M, Kelso J. High-throughput sequencing of the melanoma genome. Exp Dermatol. 2013;22(1):10–7.
https://doi.org/10.1111/exd.12054 DOI: https://doi.org/10.1111/exd.12054
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–14.
https://doi.org/10.1056/NEJMoa1203421 DOI: https://doi.org/10.1056/NEJMoa1203421
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–703.
https://doi.org/10.1056/NEJMoa1210093 DOI: https://doi.org/10.1056/NEJMoa1210093
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–9.
https://doi.org/10.1093/annonc/mdx176 DOI: https://doi.org/10.1093/annonc/mdx176
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27.
https://doi.org/10.1016/s1470-2045(18)30497-2 DOI: https://doi.org/10.1016/S1470-2045(18)30497-2
Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60.
https://doi.org/10.1016/s1470-2045(16)30122-x DOI: https://doi.org/10.1016/S1470-2045(16)30122-X
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1): 30–9.
https://doi.org/10.1056/NEJMoa1412690 DOI: https://doi.org/10.1056/NEJMoa1412690
Mincu RI, Mahabadi AA, Michel L, Mrotzek SM, Schadendorf D, Rassaf T, et al. Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(8):e198890.
https://doi.org/10.1001/jamanetworkopen.2019.8890 DOI: https://doi.org/10.1001/jamanetworkopen.2019.8890
Glen C, Tan YY, Waterston A, Evans TRJ, Jones RJ, Petrie MC, et al. Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK inhibitors: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022;4(1):1–18.
https://doi.org/10.1016/j.jaccao.2022.01.096 DOI: https://doi.org/10.1016/j.jaccao.2022.01.096
Livingstone E, Zimmer L, Vaubel J, Schadendorf D. BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management. Chin Clin Oncol. 2014;3(3):29.
https://doi.org/10.3978/j.issn.2304-3865.2014.03.03
Banks M, Crowell K, Proctor A, Jensen BC. Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism. Cardiovasc Toxicol. 2017;17(4):487–93.
https://doi.org/10.1007/s12012-017-9425-z DOI: https://doi.org/10.1007/s12012-017-9425-z
Daud A, Tsai K. Management of treatment-related adverse events with agents targeting the MAPK pathway in patients with metastatic melanoma. Oncologist. 2017;22(7):823–33.
https://doi.org/10.1634/theoncologist.2016-0456 DOI: https://doi.org/10.1634/theoncologist.2016-0456
Guha A, Jain P, Fradley MG, Lenihan D, Gutierrez JM, Jain C, et al. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries. Cancer Med. 2021;10(12):3862–72.
https://doi.org/10.1002/cam4.3938 DOI: https://doi.org/10.1002/cam4.3938
Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis. J Glob Oncol. 2015;1(2):73–82.
https://doi.org/10.1200/jgo.2015.000802 DOI: https://doi.org/10.1200/JGO.2015.000802
Barnea R, Berger R, Weiss Y, Shemer J. Less is more (healthy): overuse of healthcare services. Isr Med Assoc J. 2022;24(6):403–9.
Ellebaek E, Svane IM, Schmidt H, Haslund CA, Donia M, Hoejberg L, et al. The Danish metastatic melanoma database (DAMMED): a nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. Cancer Epidemiol. 2021;73:101943.
https://doi.org/10.1016/j.canep.2021.101943 DOI: https://doi.org/10.1016/j.canep.2021.101943
Khouri MG, Douglas PS, Mackey JR, Martin M, Scott JM, Scherrer-Crosbie M, et al. Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues. Circulation. 2012;126(23):2749–63.
https://doi.org/10.1161/circulationaha.112.100560 DOI: https://doi.org/10.1161/CIRCULATIONAHA.112.100560
Pedersen S, Larsen KO, Christensen AH, Svane IM, Zerahn B, Ellebaek E. Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting. Acta Oncol. 2022;61(1): 45–51.
https://doi.org/10.1080/0284186x.2021.1992010 DOI: https://doi.org/10.1080/0284186X.2021.1992010
Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27(9):911–39.
https://doi.org/10.1016/j.echo.2014.07.012 DOI: https://doi.org/10.1016/j.echo.2014.07.012
Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer therapy-related cardiac dysfunction: an overview for the clinician. Clin Med Insights Cardiol. 2019;13:1179546819866445.
https://doi.org/10.1177/1179546819866445 DOI: https://doi.org/10.1177/1179546819866445
Chen-Scarabelli C, McRee C, Leesar MA, Hage FG, Scarabelli TM. Comprehensive review on cardio-oncology: role of multimodality imaging. J Nucl Cardiol. 2017;24(3):906–35.
https://doi.org/10.1007/s12350-016-0535-y DOI: https://doi.org/10.1007/s12350-016-0535-y
Berger M, Amini-Adlé M, Maucort-Boulch D, Robinson P, Thomas L, Dalle S, et al. Left ventricular ejection fraction decrease related to BRAF and/or MEK inhibitors in metastatic melanoma patients: a retrospective analysis. Cancer Med. 2020;9(8):2611–20.
https://doi.org/10.1002/cam4.2922 DOI: https://doi.org/10.1002/cam4.2922
Printezi MI, Yousif LIE, Kamphuis JAM, van Laake LW, Cramer MJ, Hobbelink MGG, et al. LVEF by multigated acquisition scan compared to other imaging modalities in cardio-oncology: a systematic review. Curr Heart Fail Rep. 2022;19(3):136–45.
https://doi.org/10.1007/s11897-022-00544-3 DOI: https://doi.org/10.1007/s11897-022-00544-3
Arangalage D, Degrauwe N, Michielin O, Monney P, Özdemir BC. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treat Rev. 2021;100:102282.
https://doi.org/10.1016/j.ctrv.2021.102282 DOI: https://doi.org/10.1016/j.ctrv.2021.102282
Shah RR, Morganroth J. Update on cardiovascular safety of tyrosine kinase inhibitors: with a special focus on QT interval, left ventricular dysfunction and overall risk/benefit. Drug Saf. 2015;38(8):693–710.
https://doi.org/10.1007/s40264-015-0300-1 DOI: https://doi.org/10.1007/s40264-015-0300-1
Erbel R, Schweizer P, Krebs W, Langen HJ, Meyer J, Effert S. Effects of heart rate changes on left ventricular volume and ejection fraction: a 2-dimensional echocardiographic study. Am J Cardiol. 1984;53(4):590–7.
https://doi.org/10.1016/0002-9149(84)90036-5 DOI: https://doi.org/10.1016/0002-9149(84)90036-5
von Haehling S, Lainscak M, Kung T, Cramer L, Fülster S, Pelzer U, et al. Non-invasive assessment of cardiac hemodynamics in patients with advanced cancer and with chronic heart failure: a pilot feasibility study. Arch Med Sci. 2013;9(2):261–7.
https://doi.org/10.5114/aoms.2013.34574 DOI: https://doi.org/10.5114/aoms.2013.34574
Anker MS, Ebner N, Hildebrandt B, Springer J, Sinn M, Riess H, et al. Resting heart rate is an independent predictor of death in patients with colorectal, pancreatic, and non-small cell lung cancer: results of a prospective cardiovascular long-term study. Eur J Heart Fail. 2016;18(12):1524–34.
https://doi.org/10.1002/ejhf.670 DOI: https://doi.org/10.1002/ejhf.670
Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4(3):9.
https://doi.org/10.1136/esmoopen-2019-000491 DOI: https://doi.org/10.1136/esmoopen-2019-000491
Gawlik M, Zimodro JM, Gąsecka A, Filipiak KJ, Szmit S. Cardiac arrhythmias in oncological patients – epidemiology, risk factors, and management within the context of the New ESC 2022 guidelines. Curr Oncol Rep. 2023;25(10):1107–15.
https://doi.org/10.1007/s11912-023-01445-x DOI: https://doi.org/10.1007/s11912-023-01445-x
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Jonas K. Oddershede, Ida K. Meklenborg, Lars Bastholt, Louise M. Guldbrandt, Henrik Schmidt, Rasmus B. Friis
This work is licensed under a Creative Commons Attribution 4.0 International License.
